Premium
Cerebro‐Vasculoprotective Effects of Azilsartan Medoxomil in Diabetes
Author(s) -
Abdelsaid Mohammed A,
Coucha Maha M,
Ergul Adviye
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1169.13
Subject(s) - blood pressure , diabetes mellitus , glycemic , medicine , type 2 diabetes , endocrinology
We have shown that glycemic control prevents diabetes‐mediated remodeling of the cerebrovasculature. However, whether the remodeling can be reversed is unknown. Given that angiotensin II Type 1 receptor blockers (ARBs) reverse pathological vascular remodeling and function independent of changes in blood pressure in other vascular beds, we hypothesized that azilsartan medoxomil, a new ARB, reverses cerebrovascular remodeling in diabetes independent of blood pressure. Methods Control Wistar and diabetic Goto‐Kakizaki rats (n=20/group), were treated with vehicle (water) or Azilsartan medoxomil (3 mg/kg/day) from 18 to 22 weeks of age. Blood glucose and blood pressure was monitored and middle cerebral artery structure and function was evaluated using pressurized arteriography. Results Blood glucose was higher in the GK compared to Wistar rats. Azilsartan treatment lowered blood glucose. There was no difference in blood pressure among the groups. Diabetic animals exhibited lower myogenic tone, increased wall thickness, and cross sectional area compared to controls which were corrected by azilsartan treatment. Conclusion Azilsartan medoxomil restores diabetes‐induced cerebrovascular remodeling independent of blood pressure. This effect may be partially mediated by improvement of blood glucose. Disclosure The project is supported by Takeda Pharmaceuticals North America Inc.